New preclinical data from the ChromaDex External Research
Program (CERP) shows positive effects of nicotinamide riboside (NR)
in glaucoma, Alzheimer’s disease, and cardiac ischemia-reperfusion
injury mouse models
ChromaDex Corp. (NASDAQ:CDXC) today announced findings from
recently published preclinical studies, as well as recently
registered clinical research, investigating Niagen® (patented
nicotinamide riboside, or “NR”) in various health outcomes. Through
the industry-leading ChromaDex External Research Program (CERP™),
ChromaDex supplies Niagen® to researchers around the world at no
cost to help advance the understanding of NR’s impact on various
age-related health conditions.
A recent publication in the journal Pharmaceutics found that
preventative, systemic administration of NR improved retinal
ganglion cell (RGC) survival in both acute and chronic preclinical
models of glaucoma. This is the first study to demonstrate that
systemic treatment with NR is protective in acute and chronic
models of RGC damage and builds on the growing body of preclinical
evidence on NR’s role in eye health.
A second newly published study in the Proceedings of the
National Academy of Sciences (PNAS), demonstrated administration of
NR in a mouse model of Alzheimer's Disease (AD) increased brain
NAD+ levels and reduced neuroinflammation, DNA damage, and cellular
senescence. NR also improved learning and memory in the AD mice.
Overall, these findings provide important insights into the
interconnection between NR, cellular senescence, and
neuroinflammation in AD and warrant further investigation.
A third study published in Frontiers in Cardiovascular Medicine
investigated the efficacy of cardioprotective compounds such as
fingolimod (Fingo), empagliflozin (Empa), melatonin (Mela), and NR,
in a mouse model of cardiac ischemia-reperfusion injury (IRI). Of
the compounds tested, only acute administration of NR significantly
reduced cardiac IRI in the presence of clinically relevant
anesthesia and anticoagulation therapy such as fentanyl, midazolam,
and cangrelor. Therefore, the researchers suggested NR is most
suitable for a multitarget cardioprotective strategy. However,
further research is necessary to test the efficacy of NR prior to
clinical use.
In addition, ChromaDex is the supplier of Niagen® for two
recently registered trials on ClinicalTrials.gov. The first trial
is investigating the effect of dietary supplementation of NR in
children with ataxia-telangiectasia (AT), with the main focus on
neurological symptoms. The second trial is exploring whether
combined treatment of exercise and Niagen® will show greater
improvements in skeletal muscle mitochondrial metabolism compared
to exercise alone.
Frank Jaksch, ChromaDex Co-Founder & Executive Chairman,
recently presented studies conducted through CERP™ investigating
the effects of NR on orphan diseases at this year’s Aging Research
& Drug Discovery Conference (ARDD) in Copenhagen, Denmark, and
encouraged researchers interested in researching NAD+ precursors to
apply to CERP™.
Since 2013, CERP™ has accumulated more than 235 collaborative
agreements representing $85 million in total research investment.
The program has also resulted in numerous patent applications and
licenses. Additionally, through CERP™ to date, Niagen® has been a
part of more than 65 publications, including 13 peer-reviewed,
clinical trial publications.
The role of the NAD+ (nicotinamide adenine dinucleotide)
boosting benefits of NR was first discovered in 2004 by Dr. Charles
Brenner, the Alfred E Mann Family Foundation Chair in Diabetes and
Cancer Metabolism at City of Hope National Medical Center and
ChromaDex Chief Scientific Advisor.
Since then, ChromaDex has made substantial investments to
investigate, license, manufacture and commercialize its patented
nicotinamide riboside, Niagen®, showing safety and efficacy at
boosting NAD+ levels in nine published human studies and obtaining
regulatory acceptance in the United States, Canada, the European
Union, and Australia.
For additional information on the science supporting Niagen®
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to results of the NIAGEN®
studies, their significance and whether the studies show potential
for benefits on human health. Statements that are not a description
of historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210920005122/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024